FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Heather Davis

Research Profile

Living Beings

Chemicals & Drugs

Physiology

Anatomy

Disorders

Hepatitis B

Procedures

Co-author Network

Publications

TOP 3
Curtis L Cooper; Jonathan B Angel; Isabelle Seguin; Heather L Davis; William Cameron
CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years.
Curtis L Cooper; Navneet K Ahluwalia; Susan M Efler; Jörg Vollmer; Arthur M Krieg; Heather L Davis
Immunostimulatory effects of three classes of CpG oligodeoxynucleotides on PBMC from HCV chronic carriers.
John G McHutchison; Bruce R Bacon; Stuart Gordon; Eric Lawitz; Mitchell Shiffman; Nezam H Afdhal; Ira M Jacobson; Andrew Muir; Mohammed J Al Adhami; Mary Lou Morris; Julie Lekstrom-Himes; Susan M Efler; Heather L Davis
Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Heather Davis (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2008: Curtis L Cooper; Jonathan B Angel; Isabelle Seguin; Heather L Davis; William Cameron
CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2008;46(8):1310-4.
2008: Curtis L Cooper; Navneet K Ahluwalia; Susan M Efler; Jörg Vollmer; Arthur M Krieg; Heather L Davis
Immunostimulatory effects of three classes of CpG oligodeoxynucleotides on PBMC from HCV chronic carriers.
Journal of immune based therapies and vaccines 2008;6():3.
2007: John G McHutchison; Bruce R Bacon; Stuart Gordon; Eric Lawitz; Mitchell Shiffman; Nezam H Afdhal; Ira M Jacobson; Andrew Muir; Mohammed J Al Adhami; Mary Lou Morris; Julie Lekstrom-Himes; Susan M Efler; Heather L Davis
Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus.
Hepatology (Baltimore, Md.) 2007;46(5):1341-9.
2007: Alain P Vicari; Tess Schmalbach; Julie Lekstrom-Himes; Mary Lou Morris; Mohammed J Al Adhami; Chantal Laframboise; Philip Leese; Arthur M Krieg; Susan M Efler; Heather L Davis
Safety, pharmacokinetics and immune effects in normal volunteers of CPG 10101 (ACTILON), an investigational synthetic toll-like receptor 9 agonist.
Antiviral therapy 2007;12(5):741-51.
2006: Michael J McCluskie; Janna L M Cartier; Amy J Patrick; Dusan Sajic; Risini D Weeratna; Kenneth L Rosenthal; Heather L Davis
Treatment of intravaginal HSV-2 infection in mice: a comparison of CpG oligodeoxynucleotides and resiquimod (R-848).
Antiviral research 2006;69(2):77-85.
2006: Paul J Payette; Xiaoying Ma; Risini D Weeratna; Michael J McCluskie; Max Shapiro; ronald engle; Heather L Davis; Robert Purcell
Testing of CpG-optimized protein and DNA vaccines against the hepatitis B virus in chimpanzees for immunogenicity and protection from challenge.
Intervirology 2006;49(3):144-51.
2005: Risini D Weeratna; Shawn R Makinen; Michael J McCluskie; Heather L Davis
TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848).
Vaccine 2005;23(45):5263-70.
2005: Curtis L Cooper; Heather L Davis; Jonathan B Angel; Mary Lou Morris; Sue M Elfer; Isabelle Seguin; Arthur M Krieg; William Cameron
CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults.
AIDS (London, England) 2005;19(14):1473-9.
2005: Bernhard O Noll; Michael J McCluskie; Tanja Sniatala; Angela Lohner; Stephanie Yuill; Arthur M Krieg; Christian Schetter; Heather L Davis; Eugen Uhlmann
Biodistribution and metabolism of immunostimulatory oligodeoxynucleotide CPG 7909 in mouse and rat tissues following subcutaneous administration.
Biochemical pharmacology 2005;69(6):981-91.
2005: Susan M Efler; L Zhang; B O Noll; Eugen Uhlmann; Heather L Davis
Quantification of oligodeoxynucleotides in human plasma with a novel hybridization assay offers greatly enhanced sensitivity over capillary gel electrophoresis.
Oligonucleotides 2005;15(2):119-31.
2004: Claire-Anne Siegrist; Maria Pihlgren; Chantal Tougne; Susan M Efler; Mary Lou Morris; Mohammed J AlAdhami; William Cameron; Curtis L Cooper; Jenny Heathcote; Heather L Davis; Paul-Henri Lambert
Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response.
Vaccine 2004;23(5):615-22.
2004: Curtis L Cooper; Heather L Davis; Mary Lou Morris; Susan M Efler; M Al Adhami; Arthur M Krieg; William Cameron; J Heathcote
CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study.
Journal of clinical immunology 2004;24(6):693-701.
2004: Arthur M Krieg; Susan M Efler; Michael Wittpoth; Mohammed J Al Adhami; Heather L Davis
Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2004;27(6):460-71.
2004: Jörg Vollmer; Risini D Weeratna; Marion Jurk; Ulrike Samulowitz; Michael J McCluskie; Paul Payette; Heather L Davis; Christian Schetter; Arthur M Krieg
Oligodeoxynucleotides lacking CpG dinucleotides mediate Toll-like receptor 9 dependent T helper type 2 biased immune stimulation.
Immunology 2004;113(2):212-23.
2004: Jörg Vollmer; Risini D Weeratna; Marion Jurk; Heather L Davis; Christian Schetter; Meike Wüllner; Tanja Wader; Ming Liu; Andrea Kritzler; Arthur M Krieg
Impact of modifications of heterocyclic bases in CpG dinucleotides on their immune-modulatory activity.
Journal of leukocyte biology 2004;76(3):585-93.
2004: Curtis L Cooper; Heather L Davis; Mary Lou Morris; Susan M Efler; Arthur M Krieg; Y Li; C Laframboise; Mohammed J Al Adhami; Yasmin Khaliq; Isabelle Seguin; William Cameron
Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine.
Vaccine 2004;22(23-24):3136-43.
2004: Jörg Vollmer; Risini D Weeratna; Paul Payette; Marion Jurk; Christian Schetter; Meike Laucht; Tanja Wader; Sibylle Tluk; Ming Liu; Heather L Davis; Arthur M Krieg
Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities.
European journal of immunology 2004;34(1):251-62.
2003: Dusan Sajic; Ali A Ashkar; Amy J Patrick; Michael J McCluskie; Heather L Davis; Kenneth L Levine; Richard Holl; Kenneth L Rosenthal
Parameters of CpG oligodeoxynucleotide-induced protection against intravaginal HSV-2 challenge.
Journal of medical virology 2003;71(4):561-8.
2003: Risini D Weeratna; Lacrimioara Comanita; Heather L Davis
CPG ODN allows lower dose of antigen against hepatitis B surface antigen in BALB/c mice.
Immunology and cell biology 2003;81(1):59-62.
2002: Nancy Dumais; Amy J Patrick; Ronald B Moss; Heather L Davis; Kenneth L Rosenthal
Mucosal immunization with inactivated human immunodeficiency virus plus CpG oligodeoxynucleotides induces genital immune responses and protection against intravaginal challenge.
The Journal of infectious diseases 2002;186(8):1098-105.
2002: Xiaoying Ma; Xavier Forns; Robin A Gutierrez; Isa K Mushahwar; Tong Wu; Paul J Payette; Jens Bukh; Robert Purcell; Heather L Davis
DNA-based vaccination against hepatitis C virus (HCV): effect of expressing different forms of HCV E2 protein and use of CpG-optimized vectors in mice.
Vaccine 2002;20(27-28):3263-71.
2002: Anthony H-C Choi; Monica M McNeal; Jason A Flint; Mitali Basu; Nils Lycke; John Clements; Judy A Bean; Heather L Davis; Michael J McCluskie; John L VanCott; Richard L Ward
The level of protection against rotavirus shedding in mice following immunization with a chimeric VP6 protein is dependent on the route and the coadministered adjuvant.
Vaccine 2002;20(13-14):1733-40.
2002: Michael J McCluskie; Risini D Weeratna; Paul J Payette; Heather L Davis
Parenteral and mucosal prime-boost immunization strategies in mice with hepatitis B surface antigen and CpG DNA.
FEMS immunology and medical microbiology 2002;32(3):179-85.
2001: Risini D Weeratna; T Wu; Susan M Efler; L Zhang; Heather L Davis
Designing gene therapy vectors: avoiding immune responses by using tissue-specific promoters.
Gene therapy 2001;8(24):1872-8.
2001: Risini D Weeratna; CL Brazolot Millan; Michael J McCluskie; Heather L Davis
CpG ODN can re-direct the Th bias of established Th2 immune responses in adult and young mice.
FEMS immunology and medical microbiology 2001;32(1):65-71.
2001: Paul J Payette; Heather L Davis
History of vaccines and positioning of current trends.
Current drug targets. Infectious disorders 2001;1(3):241-7.
2001: Zuhair K Ballas; Arthur M Krieg; Thomas L Warren; Wendy L Rasmussen; Heather L Davis; Marianella Waldschmidt; George J Weiner
Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs.
Journal of immunology (Baltimore, Md. : 1950) 2001;167(9):4878-86.
2001: Paul J Payette; Risini D Weeratna; Michael J McCluskie; Heather L Davis
Immune-mediated destruction of transfected myocytes following DNA vaccination occurs via multiple mechanisms.
Gene therapy 2001;8(18):1395-400.
2001: Y Chen; Petar Lenert; Risini D Weeratna; Michael J McCluskie; T Wu; Heather L Davis; Arthur M Krieg
Identification of methylated CpG motifs as inhibitors of the immune stimulatory CpG motifs.
Gene therapy 2001;8(13):1024-32.
2001: E Malanchère-Brès; Paul J Payette; M Mancini; Pierre Tiollais; Heather L Davis; Marie-Louise Michel
CpG oligodeoxynucleotides with hepatitis B surface antigen (HBsAg) for vaccination in HBsAg-transgenic mice.
Journal of virology 2001;75(14):6482-91.
2001: Michael J McCluskie; Risini D Weeratna; John Clements; Heather L Davis
Mucosal immunization of mice using CpG DNA and/or mutants of the heat-labile enterotoxin of Escherichia coli as adjuvants.
Vaccine 2001;19(27):3759-68.
2001: Risini D Weeratna; CL Brazolot Millan; Michael J McCluskie; C A Siegrist; Heather L Davis
Priming of immune responses to hepatitis B surface antigen in young mice immunized in the presence of maternally derived antibodies.
FEMS immunology and medical microbiology 2001;30(3):241-7.
2001: Michael J McCluskie; Risini D Weeratna; Heather L Davis
The potential of oligodeoxynucleotides as mucosal and parenteral adjuvants.
Vaccine 2001;19(17-19):2657-60.
2001: WS Gallichan; R N Woolstencroft; T Guarasci; Michael J McCluskie; Heather L Davis; Kenneth L Rosenthal
Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract.
Journal of immunology (Baltimore, Md. : 1950) 2001;166(5):3451-7.
2001: Robert A Gramzinski; Denise L Doolan; Martha Sedegah; Heather L Davis; Arthur M Krieg; Stephen L Hoffman
Interleukin-12- and gamma interferon-dependent protection against malaria conferred by CpG oligodeoxynucleotide in mice.
Infection and immunity 2001;69(3):1643-9.
2001: A M Krieg; Heather L Davis
Enhancing vaccines with immune stimulatory CpG DNA.
Current opinion in molecular therapeutics 2001;3(1):15-24.
2001: Michael J McCluskie; Risini D Weeratna; Paul J Payette; Heather L Davis
The potential of CpG oligodeoxynucleotides as mucosal adjuvants.
Critical reviews in immunology 2001;21(1-3):103-20.
2001: Michael J McCluskie; Risini D Weeratna; Paul J Payette; Heather L Davis
The use of CpG DNA as a mucosal vaccine adjuvant.
Current opinion in investigational drugs (London, England : 2000) 2001;2(1):35-9.
2001: Jiri Kovarik; Paola Bozzotti; Chantal Tougne; Heather L Davis; Paul-Henri Lambert; Arthur M Krieg; Claire-Anne Siegrist
Adjuvant effects of CpG oligodeoxynucleotides on responses against T-independent type 2 antigens.
Immunology 2001;102(1):67-76.
2000: Michael J McCluskie; Risini D Weeratna; A M Krieg; Heather L Davis
CpG DNA is an effective oral adjuvant to protein antigens in mice.
Vaccine 2000;19(7-8):950-7.
2000: Michael J McCluskie; Heather L Davis
Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants.
Vaccine 2000;19(4-5):413-22.
2000: Michael J McCluskie; Risini D Weeratna; Heather L Davis
Intranasal immunization of mice with CpG DNA induces strong systemic and mucosal responses that are influenced by other mucosal adjuvants and antigen distribution.
Molecular medicine (Cambridge, Mass.) 2000;6(10):867-77.
2000: Xavier Forns; Paul J Payette; Xiaoying Ma; William Satterfield; Gerald Eder; Isa K Mushahwar; S Govindarajan; Heather L Davis; Suzanne U Emerson; Robert Purcell; Jens Bukh
Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV.
Hepatology (Baltimore, Md.) 2000;32(3):618-25.
2000: Heather L Davis; I I Suparto; R R Weeratna; D D Iskandriati; S S Chamzah; A A Ma'ruf; C C Nente; D D Pawitri; A M Krieg; W Smits; D D Sajuthi
CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans.
Vaccine 2000;18(18):1920-4.
2000: Risini D Weeratna; Michael J McCluskie; Y Xu; Heather L Davis
CpG DNA induces stronger immune responses with less toxicity than other adjuvants.
Vaccine 2000;18(17):1755-62.
2000: Gunther Hartmann; Risini D Weeratna; Zuhair K Ballas; Paul J Payette; Sue E Blackwell; I Suparto; Wendy L Rasmussen; Marianella Waldschmidt; D Sajuthi; Robert Purcell; Heather L Davis; Arthur M Krieg
Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo.
Journal of immunology (Baltimore, Md. : 1950) 2000;164(3):1617-24.
2000: Michael J McCluskie; Heather L Davis
Mucosal immunization with DNA vaccines.
Methods in molecular medicine 2000;29():287-95.
2000: Risini D Weeratna; A M Krieg; Heather L Davis
Immunostimulatory CpG motifs and DNA vaccines.
Methods in molecular medicine 2000;29():169-72.
2000: J Heppell; Heather L Davis
Intramuscular injection of DNA vaccines in fish.
Methods in molecular medicine 2000;29():99-103.
2000: Risini D Weeratna; Michael J McCluskie; Lacrimioara Comanita; T Wu; Heather L Davis
Optimization strategies for DNA vaccines.
Intervirology 2000;43(4-6):218-26.
2000: Michael J McCluskie; Risini D Weeratna; Heather L Davis
The role of CpG in DNA vaccines.
Springer seminars in immunopathology 2000;22(1-2):125-32.
1999: Michael J McCluskie; Heather L Davis
CpG DNA as mucosal adjuvant.
Vaccine 1999;18(3-4):231-7.
1999: Trevor R Jones; Nicanor Obaldia; Robert A Gramzinski; Yupin Charoenvit; Nelly Kolodny; Svetlana Kitov; Heather L Davis; Arthur M Krieg; Stephen L Hoffman
Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys.
Vaccine 1999;17(23-24):3065-71.
1999: Michael J McCluskie; Heather L Davis
Mucosal immunization with DNA vaccines.
Microbes and infection / Institut Pasteur 1999;1(9):685-98.
1999: Michael J McCluskie; CL Brazolot Millan; Robert A Gramzinski; H L Robinson; J C Santoro; James T Fuller; Georg Widera; Joel R Haynes; Robert Purcell; Heather L Davis
Route and method of delivery of DNA vaccine influence immune responses in mice and non-human primates.
Molecular medicine (Cambridge, Mass.) 1999;5(5):287-300.
1999: Heather L Davis
DNA vaccines for prophylactic or therapeutic immunization against hepatitis B virus.
The Mount Sinai journal of medicine, New York 1999;66(2):84-90.
1999: Jiri Kovarik; Paola Bozzotti; Laurie Love-Homan; Maria Pihlgren; Heather L Davis; Paul-Henri Lambert; Arthur M Krieg; Claire-Anne Siegrist
CpG oligodeoxynucleotides can circumvent the Th2 polarization of neonatal responses to vaccines but may fail to fully redirect Th2 responses established by neonatal priming.
Journal of immunology (Baltimore, Md. : 1950) 1999;162(3):1611-7.
1999: Heather L Davis; Michael J McCluskie
DNA vaccines for viral diseases.
Microbes and infection / Institut Pasteur 1999;1(1):7-21.
1999: Michael J McCluskie; Heather L Davis
Novel strategies using DNA for the induction of mucosal immunity.
Critical reviews in immunology 1999;19(4):303-29.
1998: CL Brazolot Millan; Risini D Weeratna; A M Krieg; C A Siegrist; Heather L Davis
CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice.
Proceedings of the National Academy of Sciences of the United States of America 1998;95(26):15553-8.
1998: Michael J McCluskie; Heather L Davis
CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice.
Journal of immunology (Baltimore, Md. : 1950) 1998;161(9):4463-6.
1998: Arthur M Krieg; T Wu; Risini D Weeratna; Susan M Efler; Laurie Love-Homan; Linda Yang; Ae-Kyung Yi; D Short; Heather L Davis
Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs.
Proceedings of the National Academy of Sciences of the United States of America 1998;95(21):12631-6.
1998: Michael J McCluskie; Y Chu; J L Xia; J Jessee; G Gebyehu; Heather L Davis
Direct gene transfer to the respiratory tract of mice with pure plasmid and lipid-formulated DNA.
Antisense & nucleic acid drug development 1998;8(5):401-14.
1998: Risini D Weeratna; CL Brazolot Millan; A M Krieg; Heather L Davis
Reduction of antigen expression from DNA vaccines by coadministered oligodeoxynucleotides.
Antisense & nucleic acid drug development 1998;8(4):351-6.
1998: Robert A Gramzinski; C L Millan; Nicanor Obaldia; Stephen L Hoffman; Heather L Davis
Immune response to a hepatitis B DNA vaccine in Aotus monkeys: a comparison of vaccine formulation, route, and method of administration.
Molecular medicine (Cambridge, Mass.) 1998;4(2):109-18.
1998: Heather L Davis; Risini D Weeratna; Thomas J Waldschmidt; Lorraine T Tygrett; J Schorr; A M Krieg; R Weeranta
CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen.
Journal of immunology (Baltimore, Md. : 1950) 1998;160(2):870-6.
1998: Michael J McCluskie; Y M Wen; Q Di; Heather L Davis
Immunization against hepatitis B virus by mucosal administration of antigen-antibody complexes.
Viral immunology 1998;11(4):245-52.
1998: Arthur M Krieg; Ae-Kyung Yi; J Schorr; Heather L Davis
The role of CpG dinucleotides in DNA vaccines.
Trends in microbiology 1998;6(1):23-7.
1998: Heather L Davis
DNA-based immunization against hepatitis B: experience with animal models.
Current topics in microbiology and immunology 1998;226():57-68.
1997: Heather L Davis; CL Brazolot Millan; M Mancini; Michael J McCluskie; michelle hadchouel; Lacrimioara Comanita; Pierre Tiollais; Robert Whalen; Marie-Louise Michel
DNA-based immunization against hepatitis B surface antigen (HBsAg) in normal and HBsAg-transgenic mice.
Vaccine 1997;15(8):849-52.
1997: A Decrouy; Jean-Marc Renaud; Heather L Davis; John A Lunde; G Dickson; Bernard J Jasmin
Mini-dystrophin gene transfer in mdx4cv diaphragm muscle fibers increases sarcolemmal stability.
Gene therapy 1997;4(5):401-8.
1997: Heather L Davis; C L Millan; simon simon watkins
Immune-mediated destruction of transfected muscle fibers after direct gene transfer with antigen-expressing plasmid DNA.
Gene therapy 1997;4(3):181-8.
1997: Heather L Davis; CL Brazolot Millan
DNA-based immunization against hepatitis B virus.
Springer seminars in immunopathology 1997;19(2):195-209.
1996: M Mancini; michelle hadchouel; Heather L Davis; Robert Whalen; Pierre Tiollais; Marie-Louise Michel
DNA-mediated immunization in a transgenic mouse model of the hepatitis B surface antigen chronic carrier state.
Proceedings of the National Academy of Sciences of the United States of America 1996;93(22):12496-501.
1996: Heather L Davis; Michael J McCluskie; J L Gerin; Robert Purcell
DNA vaccine for hepatitis B: evidence for immunogenicity in chimpanzees and comparison with other vaccines.
Proceedings of the National Academy of Sciences of the United States of America 1996;93(14):7213-8.
1996: Heather L Davis; M Schleef; P Moritz; M Mancini; J Schorr; Robert Whalen
Comparison of plasmid DNA preparation methods for direct gene transfer and genetic immunization.
BioTechniques 1996;21(1):92-4, 96-9.
1996: Heather L Davis; M Mancini; Marie-Louise Michel; Robert Whalen
DNA-mediated immunization to hepatitis B surface antigen: longevity of primary response and effect of boost.
Vaccine 1996;14(9):910-5.
1995: Robert Whalen; CLAUDE LECLERC; Edith Dériaud; R Schirmbeck; J Reimann; Heather L Davis
DNA-mediated immunization to the hepatitis B surface antigen. Activation and entrainment of the immune response.
Annals of the New York Academy of Sciences 1995;772():64-76.
1995: Heather L Davis; Marie-Louise Michel; Robert Whalen
Use of plasmid DNA for direct gene transfer and immunization.
Annals of the New York Academy of Sciences 1995;772():21-9.
1995: Heather L Davis; R Schirmbeck; J Reimann; Robert Whalen
DNA-mediated immunization in mice induces a potent MHC class I-restricted cytotoxic T lymphocyte response to the hepatitis B envelope protein.
Human gene therapy 1995;6(11):1447-56.
1995: Marie-Louise Michel; Heather L Davis; M Schleef; M Mancini; Pierre Tiollais; Robert Whalen
DNA-mediated immunization to the hepatitis B surface antigen in mice: aspects of the humoral response mimic hepatitis B viral infection in humans.
Proceedings of the National Academy of Sciences of the United States of America 1995;92(12):5307-11.
1994: Heather L Davis; Marie-Louise Michel; M Mancini; M Schleef; Robert Whalen
Direct gene transfer in skeletal muscle: plasmid DNA-based immunization against the hepatitis B virus surface antigen.
Vaccine 1994;12(16):1503-9.
1993: Heather L Davis; B A Demeneix; B Quantin; J Coulombe; Robert Whalen
Plasmid DNA is superior to viral vectors for direct gene transfer into adult mouse skeletal muscle.
Human gene therapy 1993;4(6):733-40.
1993: Heather L Davis; Marie-Louise Michel; Robert Whalen
DNA-based immunization induces continuous secretion of hepatitis B surface antigen and high levels of circulating antibody.
Human molecular genetics 1993;2(11):1847-51.
1993: Heather L Davis; Bernard J Jasmin
Direct gene transfer into mouse diaphragm.
FEBS letters 1993;333(1-2):146-50.
1993: Heather L Davis; Robert Whalen; B A Demeneix
Direct gene transfer into skeletal muscle in vivo: factors affecting efficiency of transfer and stability of expression.
Human gene therapy 1993;4(2):151-9.